NUZ.ASX: Neurizon Submits Clinical Hold Complete Response to FDA

Neurizon Submits Clinical Hold Complete Response to FDA

Stock	NUZ.ASX (NUZ.ASX)
Release Time	25 Jul 2025, 9:22 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Neurizon Submits Clinical Hold Complete Response to FDA

Key Points

Neurizon submits formal response to FDA to resolve the NUZ-001 clinical hold
Submission includes new bridging PK data to demonstrate comprehensive exposure data in rats and dogs
FDA review now underway, with feedback expected within 30 calendar days
Company targeting participation in the HEALEY ALS Platform Trial in Q4 CY2025

Full Summary

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has submitted a formal response to the United States (U.S.) Food and Drug Administration (FDA) addressing the clinical hold on its Investigational New Drug (IND) application for NUZ-001, the company's lead investigational therapy for amyotrophic lateral sclerosis (ALS). The Clinical Hold Complete Response (CHCR) includes new bridging pharmacokinetic (PK) data from 28-day studies in rats and dogs. These studies were designed to address the FDA's request for more comprehensive animal exposure data to support the safety margins of NUZ-001 and its primary sulfone metabolite. The response was submitted following constructive FDA engagement and within the company's previously guided timeline. This submission marks a significant step toward lifting the clinical hold and initiating enrolment in the HEALEY ALS Platform Trial, anticipated in Q4 2025. The new PK results demonstrate greater than 10-fold safety margins based on projected human plasma exposure levels for both NUZ-001 and its active sulfone metabolite, as well as enhanced confidence in dose selection and systemic tolerability to support progression to Phase 2/3 clinical evaluation. FDA review of the CHCR is now underway, and Neurizon expects formal feedback within 30 calendar days, in line with the FDA's standard statutory review period for hold responses. The company remains focused on advancing NUZ-001 into the HEALEY ALS Platform Trial in Q4 CY2025, subject to regulatory clearance.

Outlook

Neurizon is targeting participation in the HEALEY ALS Platform Trial in Q4 CY2025, subject to regulatory clearance.